Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Radium ra-223 dichloride
Drug ID BADD_D02586
Description Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Indications and Usage Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB08913
KEGG ID Not Available
MeSH ID Not Available
PubChem ID Not Available
TTD Drug ID Not Available
NDC Product Code 50419-208
UNII RJ00KV3VTG
Synonyms Not Available
Chemical Information
Molecular Formula Not Available
CAS Registry Number 444811-40-9
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bladder cancer recurrent20.03.04.005; 16.08.01.003-Not Available
Lung carcinoma cell type unspecified recurrent22.08.01.018; 16.19.02.005-Not Available
Metastases to abdominal cavity16.22.02.010; 07.21.03.006-Not Available
Metastases to adrenals16.22.02.012; 05.01.04.007-Not Available
Metastases to bone16.22.02.005; 15.09.03.006-Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.015-Not Available
Metastases to pleura22.05.04.002; 16.22.02.022-Not Available
Prostate cancer stage IV21.04.02.010; 16.25.01.007-Not Available
Anaemia of malignant disease01.03.04.003-Not Available
Metastases to bone marrow16.22.02.013; 01.05.01.022-Not Available
Metastases to meninges17.02.10.012; 16.22.02.003-Not Available
Postrenal failure20.01.03.021-Not Available
Metastases to soft tissue16.22.02.024; 15.09.03.020-Not Available
Bladder tamponade20.02.02.024; 24.07.01.064-Not Available
Hormone-refractory prostate cancer16.25.01.004; 21.04.02.007-Not Available
Metastases to pelvis21.07.04.008; 16.22.02.021-Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.030-Not Available
Abdominal lymphadenopathy01.09.01.020; 07.11.01.018-Not Available
Bone marrow infiltration01.05.01.018-Not Available
Internal haemorrhage24.07.01.072-Not Available
Critical illness08.01.03.065-Not Available
Bone marrow tumour cell infiltration16.21.01.005; 01.13.01.005-Not Available
Gait inability17.02.05.069; 08.01.02.011-Not Available
Illness08.01.03.091-Not Available
Metastases to gastrointestinal tract16.22.02.034; 07.21.03.010-Not Available
Metastases to spinal cord17.10.01.028; 16.22.02.042-Not Available
Myelosuppression01.03.03.015-Not Available
Physical deconditioning08.01.03.096-Not Available
The 5th Page    First    Pre   5    Total 5 Pages